The Wadhwani Innovation Network at IIT Bombay announced on October 23, 2026 a targeted grant programme to support early stage health and biotechnology ventures in India. The scheme, run in partnership with the Manipal Government of Karnataka Bioincubator, offers non dilutive funding of up to Rs 1 crore per project over a two year period to teams with technologies at Technology Readiness Level 4 or higher. The initiative is designed to help academic spinouts and startups bridge the expensive and risky development steps that take prototypes from laboratory proof of concept to market ready products.
What the grant will fund
The programme will prioritise projects that demonstrate a clear path to regulatory validation, clinical or field testing, and commercial deployment. Awardees are expected to receive not only grant funding but also access to laboratory infrastructure, mentorship from IIT Bombay and Manipal network experts, and introductions to industry partners and potential follow on investors. The grant is explicitly non dilutive, meaning recipients retain equity while receiving capital to cover prototype development, validation studies, and early stage regulatory work.
Why this matters for India’s biotech ecosystem
Translating life sciences research into viable products has long been a structural bottleneck for India’s innovation system. Academic institutions produce promising discoveries, but funding and operational support for clinical validation, biomanufacturing scale up, and regulatory navigation are scarce. Non dilutive translational grants reduce that friction by lowering the financing risk for technologies that need capital to reach demonstrable milestones that attract commercial investment.
The Wadhwani Innovation Network, backed by the Wadhwani Charitable Foundation and operating through partner centres including IIT Bombay, has been expanding a national network of translational hubs. In 2026 the network announced collaborations with philanthropic and global partners to establish Centres of Excellence and superhubs focused on health, artificial intelligence and biomanufacturing. The new Rs 1 crore grant stream complements those investments by providing project level capital targeted at moving technologies from proof of concept to proof of value.
Policy and market context
India’s central and state level policy push for a stronger bioeconomy has accelerated in recent years. The government has laid out targets for domestic biomanufacturing capacity and has launched schemes to encourage biotech startups, incubators and manufacturing. Private philanthropy and international foundations have been active in the same space, partnering with research institutions to bridge gaps in translational funding and commercialization expertise.
For startups, the availability of non dilutive capital is particularly important because early equity rounds in deep tech bio require much larger sums and longer timeframes than typical software ventures. Non dilutive grants allow founding teams to advance high impact projects without immediate dilution or the pressure of growth metrics that are inappropriate for regulated health technologies.
Potential economic effect and investor signal
By underwriting milestone driven, capital intensive stages such as preclinical validation, pilot manufacturing and regulatory studies, the grant programme can increase the pipeline of investible biotech companies emerging from Indian institutions. That should attract later stage venture capital, corporate partnerships and anchor investors looking for de risked assets. Over time, a deeper pipeline of startups passing these early milestones could support more domestic biomanufacturing and higher value jobs in research, engineering and regulatory affairs.
For multinational firms and global investors, the programme signals continued maturation of India’s translational ecosystem and an easier path to identifying technologies with validated product readiness. For states such as Karnataka, which hosts a dense cluster of research institutes and incubators, the partnership with Manipal can reinforce local innovation clusters and generate spillover benefits in services, supply chains and skilled labour markets.
Who should apply and next steps
The call is aimed at India registered startups and research teams with technologies at TRL 4 or above. Applicants are expected to set out a clear regulatory and commercial roadmap, show access to necessary institutional facilities for proposed work, and demonstrate a feasible budget and timeline for the use of grant funds over 24 months. Shortlisted teams will be invited to submit full proposals for expert review and selection.
The Wadhwani Innovation Network programme builds on earlier partnerships that have sought to scale translational activities across Indian academic institutions, and arrives amid a broader push from philanthropy and government to strengthen India’s innovation to industrialisation pipeline in health and biotechnology. For founders working on diagnostics, therapeutics, medtech or bioengineered products, the programme provides a tangible route to secure early non dilutive capital while preserving ownership ahead of larger commercial milestones.
Applications opened on October 23, 2026 with a deadline set in the programme materials. Prospective applicants are encouraged to consult the Wadhwani Innovation Network and the Manipal bioincubator for exact application criteria and timelines.